CoChat

C-peptide and metabolic outcomes in trials of disease modifying therapy in new-onset type 1 diabetes: an individual participant meta-analysis

Open access
Taylor, Peter N, Collins, Kimberly S, Lam, Anna, Karpen, Stephen R, Greeno, Brianna, Walker, Frank, Lozano, Alejandro, Atabakhsh, Elnaz, Ahmed, Simi T, Marinac, Marjana, Latres, Esther, Senior, Peter A, Rigby, Mark, Gottlieb, Peter A, Dayan, Colin M, Greenbaum, Carla, Krisher, Jeffrey, Skyler, Jay, Wherrett, Diane, Hannelius, Ulf, Lindqvist, Anton, Nowak, Christoph, Bebu, Ionut, Braffett, Barbara, Napolitano, Antonella, Jan Mohamed, Salim, Weir, Gordon, Nepom, Gerald, Beck, Roy, Richard, Claudia, Hedrick, Joseph, Ludvigsson, Johnny, Von Herrath, Matthias, Leon, Francisco, Ramos, Eleanor, Narendran, Parth, Gitelman, Stephen, Dabelea, Dana, Andrews, Rob, Haller, Michael, Jensen, Elizabeth, Harold, Kevan, Dutz, Jan · 2023 · The Lancet Diabetes & Endocrinology
Cited by 62

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

Background Metabolic outcomes in type 1 diabetes remain suboptimal. Disease modifying therapy to prevent β-cell loss presents an alternative treatment framework but the effect on metabolic outcomes is unclear. We, therefore, aimed to define the relationship between insulin C-peptide as a marker of β-cell function and metabolic outcomes in new-onset type 1 diabetes. Methods 21 trials of disease-modifying interventions within 100 days of type 1 diabetes diagnosis comprising 1315 adults (ie, those 18 years and older) and 1396 children (ie, those younger than 18 years) were combined. Endpoints assessed were stimulated area under the curve C-peptide, HbA 1c , insulin use, hypoglycaemic events, and composite scores (such as insulin dose adjusted A 1c , total daily insulin, U/kg per day, and BETA-2 score). Positive studies were defined as those meeting their primary endpoint. Differences in outcomes between active and control groups were assessed using the Wilcoxon rank test. Findings 6 months after treatment, a 24·8% greater C-peptide preservation in positive studies was associated with a 0·55% lower HbA 1c (p<0·0001), with differences being detectable as early as 3 months. Cross-sectional analysis, combining positive and negative studies, was consistent with this proportionality: a 55% improvement in C-peptide preservation was associated with 0·64% lower HbA 1c (p<0·0001). Higher initial C-peptide levels and greater preservation were associated with greater improvement in HbA 1c . For HbA 1c , IDAAC, and BETA-2 score, sample size predictions indicated that 2–3 times as many participants per group would be required to show a difference at 6 months as compared with C-peptide. Detecting a reduction in hypoglycaemia was affected by reporting methods. Interpretation Interventions that preserve β-cell function are effective at improving metabolic outcomes in new-onset type 1 diabetes, confirming their potential as adjuncts to insulin. We have shown that improvements in HbA 1c are directly proportional to the degree of C-peptide preservation, quantifying this relationship, and supporting the use of C-peptides as a surrogate endpoint in clinical trials. Funding JDRF and Diabetes UK.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2213-8587(23)00267-x

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 62

Metadata

Authors
Taylor, P. N., Collins, K. S., Lam, A., Karpen, S. R., Greeno, B., Walker, F., Lozano, A., Atabakhsh, E., Ahmed, S. T., Marinac, M., Latres, E., Senior, P. A., Rigby, M., Gottlieb, P. A., Dayan, C. M., Greenbaum, C., Krisher, J., Skyler, J., Wherrett, D., Hannelius, U., Lindqvist, A., Nowak, C., Bebu, I., Braffett, B., Napolitano, A., Jan Mohamed, S., Weir, G., Nepom, G., Beck, R., Richard, C., Hedrick, J., Ludvigsson, J., Von Herrath, M., Leon, F., Ramos, E., Narendran, P., Gitelman, S., Dabelea, D., Andrews, R., Haller, M., Jensen, E., Harold, K., & Dutz, J.
Venue
The Lancet Diabetes & Endocrinology
Publisher
Elsevier BV
Published
2023-12
Volume
11
Issue
12
Pages
915-925
ISSN
2213-8587 (ISSN-L)
OpenAlex
W4388278575
Cited by
62
References
15
FWCI
9.08
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: C-peptide and metabolic outcomes in trials of disease modifying therapy in new-onset type 1 diabetes: an individual participant meta-analysis. https://app.cochat.ai/papers/10.1016/s2213-8587(23)00267-x
The paper
Taylor, P. N., Collins, K. S., Lam, A., Karpen, S. R., Greeno, B., Walker, F., Lozano, A., Atabakhsh, E., Ahmed, S. T., Marinac, M., Latres, E., Senior, P. A., Rigby, M., Gottlieb, P. A., Dayan, C. M., Greenbaum, C., Krisher, J., Skyler, J., Wherrett, D., . . . Dutz, J. (2023). C-peptide and metabolic outcomes in trials of disease modifying therapy in new-onset type 1 diabetes: an individual participant meta-analysis. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(23)00267-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.